Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass - The LICORN randomized clinical trial

JAMA - Journal of the American Medical Association

Volumn 318, Issue 6, 2017, Pages 548-556

  Cholley, Bernard ^a   Caruba, Thibaut ^a   Grosjean, Sandrine ^b   Amour, Julien ^c   Ouattara, Alexandre ^d   Villacorta, Judith ^e   Miguet, Bertrand ^f   Guinet, Patrick ^g   Lévy, François ^h   Squara, Pierre ⁱ   Hamou, Nora Aït ^c   Carillon, Aude ^c   Boyer, Julie ^b   Boughenou, Marie Fazia ^a   Rosier, Sebastien ^g   Robin, Emmanuel ^j   Radutoiu, Mihail ^k   Durand, Michel ^l   Guidon, Catherine ^e   Desebbe, Olivier ^m   Charles Nelson, Anaïs ^a   Menasché, Philippe ^a   Rozec, Bertrand ^f   Girard, Claude ^b   Fellahi, Jean Luc ^m   Pirracchio, Romain ^a   Chatellier, Gilles ^a   more..

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b DIJON UNIVERSITY HOSPITAL   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d UNIVERSITÉ DE BORDEAUX   (France)

^e TIMONE HOSPITAL   (France)

^f CHU de Nantes   (France)

^g PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^h HÔPITAL CIVIL   (France)

ⁱ Service de réanimation CERIC   (France)

^j LILLE UNIVERSITY HOSPITAL   (France)

^k CHU CÔTE DE NACRE   (France)

^l GRENOBLE UNIVERSITY HOSPITAL   (France)

^m UNIVERSITÉ LYON 1   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOTONIC AGENT; CATECHOLAMINE; HYDRAZONE DERIVATIVE; PYRIDAZINE DERIVATIVE; SIMENDAN;

ADVERSE EFFECTS; AGED; CARDIAC OUTPUT, LOW; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; FEMALE; HEART ASSIST DEVICE; HEART STROKE VOLUME; HUMAN; INTENTION TO TREAT ANALYSIS; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; MULTICENTER STUDY; POSTOPERATIVE COMPLICATIONS; PREMEDICATION; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; TREATMENT FAILURE;

AGED; CARDIAC OUTPUT, LOW; CARDIOPULMONARY BYPASS; CARDIOTONIC AGENTS; CATECHOLAMINES; CORONARY ARTERY BYPASS; DOUBLE-BLIND METHOD; FEMALE; HEART-ASSIST DEVICES; HUMANS; HYDRAZONES; INFUSIONS, INTRAVENOUS; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PREMEDICATION; PYRIDAZINES; RENAL REPLACEMENT THERAPY; STROKE VOLUME; TREATMENT FAILURE;

EID: 85027508771     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2017.9973     Document Type: Article

References (30)

1. Algarni KD, Maganti M, Yau TM. Predictors of low cardiac output syndrome after isolated coronary artery bypass surgery: trends over 20 years. Ann Thorac Surg. 2011;92(5):1678-1684.
2. Landoni G, Bove T, Crivellari M, et al. Acute renal failure after isolated CABG surgery: six years of experience. Minerva Anestesiol. 2007;73(11):559-565.
3. Fellahi JL, Parienti JJ, Hanouz JL, Plaud B, Riou B, Ouattara A. Perioperative use of dobutamine in cardiac surgery and adverse cardiac outcome: propensity-adjusted analyses. Anesthesiology. 2008;108(6):979-987.
4. Nielsen DV, Hansen MK, Johnsen SP, Hansen M, Hindsholm K, Jakobsen CJ. Health outcomes with and without use of inotropic therapy in cardiac surgery: results of a propensity score-matched analysis. Anesthesiology. 2014;120(5):1098-1108.
5. De Hert SG, Lorsomradee S, Cromheecke S, Van der Linden PJ. The effects of levosimendan in cardiac surgery patients with poor left ventricular function [erratum in Anesth Analg.2007;104(6):1544]. Anesth Analg. 2007;104(4):766-773.
6. Eriksson HI, Jalonen JR, Heikkinen LO, et al. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Ann Thorac Surg. 2009;87(2): 448-454.
7. Tritapepe L, De Santis V, Vitale D, et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. Br J Anaesth. 2009;102(2):198-204.
8. Erb J, Beutlhauser T, Feldheiser A, et al. Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery. J Int Med Res. 2014;42(3):750-764.
9. Levin R, Degrange M, Del Mazo C, Tanus E, Porcile R. Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Exp Clin Cardiol. 2012;17(3):125-130.
10. Baysal A, Yanartas M, Dogukan M, Gundogus N, Kocak T, Koksal C. Levosimendan improves renal outcome in cardiac surgery: a randomized trial. J Cardiothorac Vasc Anesth. 2014;28(3):586-594.
11. Landoni G, Biondi-Zoccai G, Greco M, et al. Effects of levosimendan on mortality and hospitalization: a meta-analysis of randomized controlled studies. Crit Care Med. 2012;40(2):634-646.
12. Harrison RW, Hasselblad V, Mehta RH, Levin R, Harrington RA, Alexander JH. Effect of levosimendan on survival and adverse events after cardiac surgery: a meta-analysis. J Cardiothorac Vasc Anesth. 2013;27(6):1224-1232.
13. Lim JY, Deo SV, Rababa’h A, et al. Levosimendan reduces mortality in adults with left ventricular dysfunction undergoing cardiac surgery: a systematic review and meta-analysis. J Card Surg. 2015;30(7):547-554.
14. Mehta RH, Leimberger JD, van Diepen S, et al; LEVO-CTS Investigators. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. N Engl J Med. 2017;376(21):2032-2042.
15. Landoni G, Lomivorotov VV, Alvaro G, et al; CHEETAH Study Group. Levosimendan for hemodynamic support after cardiac surgery. N Engl J Med. 2017;376(21):2021-2031.
16. Caruba T, Hourton D, Sabatier B, et al. Rationale and design of the multicenter randomized trial investigating the effects of levosimendan pretreatment in patients with low ejection fraction (≤40 %) undergoing CABG with cardiopulmonary bypass (LICORN study). J Cardiothorac Surg. 2016;11 (1):127.
17. Altman DG, Bland JM. Treatment allocation by minimisation. BMJ. 2005;330(7495):843.
18. Levin RL, Degrange MA, Porcile R, et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [in Spanish]. Rev Esp Cardiol. 2008;61(5):471-479.
19. Cuzick J. Forest plots and the interpretation of subgroups. Lancet. 2005;365(9467):1308.
20. Rao V, Ivanov J, Weisel RD, Ikonomidis JS, Christakis GT, David TE. Predictors of low cardiac output syndrome after coronary artery bypass. J Thorac Cardiovasc Surg. 1996;112(1):38-51.
21. Maganti M, Badiwala M, Sheikh A, et al. Predictors of low cardiac output syndrome after isolated mitral valve surgery. J Thorac Cardiovasc Surg. 2010;140(4):790-796.
22. Jiang W, Teng J, Xu J, et al. Dynamic predictive scores for cardiac surgery–associated acute kidney injury. J Am Heart Assoc. 2016;5(8):e003754.
23. Follath F, Cleland JG, Just H, et al; Steering Committee and Investigators of the Levosimendan Infusion Versus Dobutamine (LIDO) Study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002;360(9328):196-202.
24. Bragadottir G, Redfors B, Ricksten SE. Effects of levosimendan on glomerular filtration rate, renal blood flow, and renal oxygenation after cardiac surgery with cardiopulmonary bypass: a randomized placebo-controlled study. Crit Care Med. 2013;41(10):2328-2335.
25. Zhou C, Gong J, Chen D, Wang W, Liu M, Liu B. Levosimendan for prevention of acute kidney injury after cardiac surgery: a meta-analysis of randomized controlled trials. Am J Kidney Dis. 2016; 67(3):408-416.
26. Mebazaa A, Nieminen MS, Packer M, et al; SURVIVE Investigators. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA. 2007;297(17):1883-1891.
27. Grieshaber P, Lipp S, Arnold A, et al. Impact of prophylactic administration of levosimendan on short-term and long-term outcome in high-risk patients with severely reduced left-ventricular ejection fraction undergoing cardiac surgery - a retrospective analysis. J Cardiothorac Surg. 2016;11 (1):162.
28. Lomivorotov VV, Boboshko VA, Efremov SM, et al. Levosimendan versus an intra-aortic balloon pump in high-risk cardiac patients. J Cardiothorac Vasc Anesth. 2012;26(4):596-603.
29. Toller W, Heringlake M, Guarracino F, et al. Preoperative and perioperative use of levosimendan in cardiac surgery: European expert opinion. Int J Cardiol. 2015;184:323-336.
30. Papp Z, Édes I, Fruhwald S, et al. Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol. 2012;159(2):82-87.